What Is Atara Biotherapeutics, Inc. (ATRA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Atara Biotherapeutics, Inc.'s intrinsic value is estimated at $14.25, suggesting a +64.4% average upside from the current price of $8.67. While 7 models see room for appreciation, model agreement is not unanimous as 5 models flag potential overvaluation. Model dispersion is worth noting: EPV targets $49.72 (+473.4%), versus Sentiment SOTP at $1.38 (-84.1%). This +557.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ATRA?
12 of 13 models are currently active for ATRA. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates ATRA's intrinsic value at $2.64, implying -69.5% downside from the current price. See which stocks rank higher →
How Does ATRA Rank in Biological Products, (No Diagnostic Substances)?
Among 139 Biological Products, (No Diagnostic Substances) stocks, ATRA ranks #105 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Atara Biotherapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is ATRA a Value Trap?
CirclFi's Value Trap algorithm assigns ATRA a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Atara Biotherapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Atara Biotherapeutics, Inc. scores 4.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +557.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ATRA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ATRA's 12 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad